Orphenadrine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Orphenadrine
- Orphenadrine: From Parkinsonian Disorder to Retinal Dystrophy (with or without Extraocular Anomalies)
Orphenadrine: From Parkinsonian Disorder to Retinal Dystrophy (with or without Extraocular Anomalies)
One-Sentence Summary
Orphenadrine is an anticholinergic, antihistaminic agent with NMDA-channel-blocking activity, originally used for parkinsonian disorders and Parkinson disease. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinsonian disorder; Parkinson disease |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 11 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, orphenadrine is an anticholinergic/antihistaminic agent with NMDA-antagonist activity. Its efficacy in parkinsonian disorders is established, but nothing in the data compiled for this report connects these actions to inherited retinal degeneration.
Retinal dystrophy is a hereditary degenerative condition. Orphenadrine's pharmacology (muscarinic and H1 antagonism, NMDA channel block) has no known disease-modifying link to it. The high TxGNN score reflects a knowledge-graph prediction only, so this should be treated as a hypothesis, not a supported finding.
Other top-ranked predictions for this drug are also weakly supported. The only candidate with any literature is schizophrenia (rank 5, score 99.13%, evidence level L3). There, orphenadrine has mainly been studied as an adjunct for antipsychotic-induced extrapyramidal symptoms, which is management of drug side effects rather than disease treatment. The literature is mostly old, and Cochrane reviews note that anticholinergics may worsen tardive dyskinesia. It is flagged as a research question, not a recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the primary predicted indication (retinal dystrophy).
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07611P | ONADRINE TABLET 50 mg | Tablet | Not stated |
| SIN05771P | CETAGESIC TABLET | Tablet | Not stated |
| SIN05552P | NORGESIC TABLET | Tablet | Not stated |
| SIN05937P | SUNITON TABLETS | Tablet | Not stated |
| SIN09867P | CAMGESIC TABLET | Tablet | Not stated |
Six further valid single-ingredient registrations exist (11 in total), covering tablets, film-coated tablets and capsules, all oral.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): hypertension, liver failure, liver disease, kidney disease and impaired renal function, epilepsy, insomnia, glaucoma, benign prostatic hyperplasia, bladder neck obstruction, pyloric stenosis, achalasia and megaesophagus, peptic ulcer disease, myasthenia gravis and other neuromuscular junction disease, heart conduction disease, sudden cardiac arrest, thrombocytopenia, anaemia, hemophilia, gout, gallbladder disease, substance abuse/dependence, paracetamol poisoning, and pyoureter.
- Drug Interactions: 100 interactions were found. Major interactions include morphine (including liposomal), potassium chloride and potassium citrate. Moderate interactions include other anticholinergics (hyoscyamine, atropine, glycopyrronium, dicyclomine, clidinium, mepenzolate, methscopolamine, propantheline), loperamide, bupropion, metoclopramide, dronabinol, nabilone, eluxadoline and opium.
The glaucoma contraindication deserves particular attention for any eye-related use. Please also refer to the package insert for label warnings.
Conclusion and Next Steps
Decision: Hold
Rationale: The retinal dystrophy prediction rests only on a knowledge-graph score, with no trials, no literature and no plausible mechanism. Orphenadrine's anticholinergic burden and the glaucoma contraindication add concern for an eye-related use.
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale linking orphenadrine to retinal degeneration
- Preclinical evidence in relevant retinal models
- HSA package insert warnings and contraindications (a blocking data gap for safety screening)
- Approved indication text for the Singapore registrations, which is currently blank
- If pursuing the better-supported schizophrenia direction, a systematic review of the benefit-risk balance, given the old and low-quality evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.